Company research / BLFS

Biolife Solutions Inc (BLFS)

SEC name BIOLIFE SOLUTIONS INC · CIK 0000834365 · Nasdaq · Electromedical & Electrotherapeutic Apparatus

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Biolife Solutions Inc reported revenue of $96.21M. Revenue grew 28.9% from the prior annual period.

Key ratios (year ended 2025-12-31)

64.6%
Gross margin
-17.3%
Operating margin
-4.8%
Net margin
-1.2%
Return on year-end equity
28.9%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-10-08

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Stock splits: 1-for-14, first reflected in a filing dated 2014-02-12. Figures are as filed: per-share figures and share counts last reported before a split are on the old share basis, so changes and growth rates across a split are not shown. Splits are read from the filings' own restatements, so a share conversion in a merger or reorganization shows up the same way.

Period endedTTM to
2026-06-30
2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312019-09-302019-06-302019-03-31
Revenuen/a$96.21M$74.65M$68.02M$76.24M$119.16M$48.09M$27.37Mn/an/an/a
Cost of Revenue$38.82M$34.10M$24.55M$26.70Mn/an/an/an/an/an/an/a
Gross Profit$67.87M$62.12M$50.10M$41.32Mn/an/an/an/an/an/an/a
R&D Expensen/a$7.57M$4.75M$5.51M$8.67M$11.82M$6.72M$3.17Mn/an/an/a
Operating Incomen/a-$16.60M-$4.48M-$17.20M-$5.92M-$35.16M-$6.24M-$220.0Kn/an/an/a
Depreciation & Amortization$1.68M$2.25M$5.16M$7.11M$6.78M$4.66M$2.04M$718.0Kn/an/an/a
EBITDAn/a-$14.35M$683.0K-$10.09M$852.0K-$30.50M-$4.21M$498.0Kn/an/an/a
Net Income$57.98M-$4.59M-$20.18M-$68.00M-$139.81M-$8.91M$1.98M-$1.66Mn/an/an/a
EPS (Diluted)n/a-$0.10-$0.44-$1.55-$3.25-$0.23-$0.06-$0.09n/an/an/a
Total Assets$447.49M$405.88M$399.49M$412.71M$450.23M$554.29M$234.83M$92.82M$83.79M$51.30M$48.07M
Total Liabilities$27.49M$34.00M$50.58M$75.05M$86.04M$76.24M$29.58M$49.36M$48.60M$49.23M$51.81M
Long-Term Debt$0$5.00M$15.94M$23.85M$25.61M$7.21M$1.27M$13.0Kn/an/an/a
Shareholders' Equity$420.00M$371.89M$348.91M$337.66M$364.19M$478.05M$204.43M$43.45M$35.19M$2.07M-$3.74M
Cash & Equivalents$24.00M$33.04M$91.54M$27.90M$19.44M$69.86M$90.40M$6.45M$21.20M$19.62M$31.82M
Operating Cash Flow$16.88M$20.11M$8.43M-$12.50M-$8.49M-$4.59M$6.64M$1.21Mn/an/an/a
Capital Expenditures$8.77M$9.48M$3.23M$6.38M$10.38M$8.38M$1.96M$675.0Kn/an/an/a
Free Cash Flow$8.11M$10.64M$5.20M-$18.88M-$18.87M-$12.98M$4.68M$538.0Kn/an/an/a
Shares Outstanding48.89M48.20M46.91M45.17M42.83M41.82M33.04M20.83M20.34M18.90M18.72M
Weighted Average Diluted Sharesn/a48.65M46.07M43.72M43.07M38.50Mn/an/an/an/an/a
EPS (Basic)n/a-$0.09-$0.44-$1.55-$3.29-$0.23$0.07-$0.09n/an/an/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView